UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 47.

Huang, J; Beyer, C; Palumbo-Zerr, K; Zhang, Y; Ramming, A; Distler, A; Gelse, K; Distler, O; Schett, G; Wollin, L; Distler, J H W (2016). Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 75(5):883-890.

Wohlfahrt, T; Usherenko, S; Englbrecht, M; Dees, C; Weber, S; Beyer, C; Gelse, K; Distler, O; Schett, G; Distler, J H W; Ramming, A (2016). Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 75(3):623-626.

Ramming, A; Distler, J H W; Schett, G; Gay, S; Jüngel, A (2014). Epigenetische Modifikationen bei Autoimmunerkrankungen. Zeitschrift für Rheumatologie, 73(7):636-638.

Beyer, C; Distler, O; Distler, J H W (2012). Biomarkers of fibrosis. In: Varga, J; Denton, C P; Wigley, F M. Scleroderma: From Pathogenesis to Comprehensive Management. Boston: Springer, 283-290.

Avouac, J; Palumbo, K; Tomcik, M; Zerr, P; Dees, C; Horn, A; Maurer, B; Akhmetshina, A; Beyer, C; Sadowski, A; Schneider, H; Shiozawa, S; Distler, O; Schett, G; Allanore, Y; Distler, J H W (2012). Inhibition of AP-1 signaling abrogates TGF-ß mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 64(5):1642-1652.

Distler, J H W; Strapatsas, T; Huscher, D; Dees, C; Akhmetshina, A; Kiener, H P; Tarner, I H; Maurer, B; Walder, M; Michel, B; Gay, S; Smolen, J S; Müller-Ladner, U; Schett, G; Distler, O (2011). Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 70(7):1197-1202.

Beyer, C; Distler, J H W; Allanore, Y; Aringer, M; Avouac, J; Czirják, L; Cutolo, M; Damjanov, N; Del Galdo, F; Fligelstone, K; Guiducci, S; Kowal-Bielecka, O; van Laar, J M; Martucci-Cerinic, M; Müller-Ladner, U; Riemekasten, G; Tarner, I H; Tyndall, A; Kennedy, A T; Valentini, G; Vettori, S; Walker, U A; Denton, C; Distler, O (2011). EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 70(7):1178-1182.

Lang, V; Distler, O; Distler, J H W (2011). Early and late pathological events in scleroderma. Kilchberg, Schweiz: European League Against Rheumatism EULAR.

Jüngel, A; Distler, J H W; Gay, S; Distler, O (2011). Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert Review of Clinical Immunology, 7(4):475-480.

Iwamoto, N; Distler, O (2011). In depths discussion: Potential vascular and fibrotic targets for drug intervention. Kilchberg, Schweiz: European League Against Rheumatism EULAR.

Avouac, J; Fürnrohr, B G; Tomcik, M; Palumbo, K; Zerr, P; Horn, A; Dees, C; Akhmetshina, A; Beyer, C; Distler, O; Schett, G; Allanore, Y; Distler, J H W (2011). Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 63(3):800-809.

Distler, J H W; Akhmetshina, A; Dees, C; Jüngel, A; Stürzl, M; Gay, S; Pisetsky, D S; Schett, G; Distler, O (2011). Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis and Rheumatism, 63(7):2067-2077.

Dees, C; Zerr, P; Tomcik, M; Beyer, C; Horn, A; Akhmetshina, A; Palumbo, K; Reich, N; Zwerina, J; Sticherling, M; Mattson, M P; Distler, O; Schett, G; Distler, J H W (2011). Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 63(5):1396-1404.

Bergmann, C; Akhmetshina, A; Dees, C; Palumbo, K; Zerr, P; Beyer, C; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2011). Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Annals of the Rheumatic Diseases, 70(12):2191-2198.

Distler, J H W; Jordan, S; Airo, P; Alegre-Sancho, J J; Allanore, Y; Balbir Gurman, A; Caporali, R; Caramaschi, P; Carreira, P E; Chizzolini, C; Cutolo, M; Tuncay Duruöz, M; Farge-Bancel, D; Hesselstrand, R; Iannone, F; De Keyser, F; Kucharz, E J; Launay, D; García de la Peña Lefebvre, P; Lukacova, O; Marasini, B; Martinovic, D; Marques Neto, J F; Radic, M; Rednic, S; Riemekasten, G; Rovensky, J; Seidel, M F; Senel, S; Smith, V; Sunderkötter, C; Ton, E; van Laar, J M; Matucci-Cerinic, M; Müller Ladner, U; Distler, O (2011). Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clinical and Experimental Rheumatology, 29(2 Suppl 65):S40-S45.

Guiducci, S; Ricci, L; Romano, E; Ceccarelli, C; Distler, J H W; Miniati, I; Calabri, G B; Distler, O; Matucci Cerinic, M; Falcini, F (2011). Microparticles and Kawasaki disease: a marker of vascular damage? Clinical and Experimental Rheumatology, 29(1 Suppl 64):S121-S125.

Reich, N; Beyer, C; Gelse, K; Akhmetshina, A; Dees, C; Zwerina, J; Schett, G; Distler, O; Distler, J H W (2011). Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. Journal of Cellular and Molecular Medicine, 15(4):756-762.

Dees, C; Tomcik, M; Zerr, P; Akhmetshina, A; Horn, A; Palumbo, K; Beyer, C; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2011). Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 70(7):1304-1310.

Dees, C; Akhmetshina, A; Zerr, P; Reich, N; Palumbo, K; Horn, A; Jüngel, A; Beyer, C; Krönke, G; Zwerina, J; Reiter, R; Alenina, N; Maroteaux, L; Gay, S; Schett, G; Distler, O; Distler, J H W (2011). Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine, 208(5):961-972.

Palumbo, K; Zerr, P; Tomcik, M; Vollath, S; Dees, C; Akhmetshina, A; Avouac, J; Yaniv, M; Distler, O; Schett, G; Distler, J H W (2011). The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 70(7):1320-1326.

Iwamoto, N; Distler, J H W; Distler, O (2011). Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Current Rheumatology Reports, 13(1):21-7.

Beyer, C; Schett, G; Distler, O; Distler, J H W (2010). Animal models of systemic sclerosis: Prospects and limitations. Arthritis and Rheumatism, 62(10):2831-2844.

Beyer, C; Distler, J H W; Distler, O (2010). Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Medical Weekly, 140:w13050.

Maciejewska Rodrigues, H; Al-Shamisi, M; Hemmatazad, H; Ospelt, C; Bouton, M C; Jäger, D; Cope, A P; Charles, P; Plant, D; Distler, J H W; Gay, R E; Michel, B A; Knuth, A; Neidhart, M; Gay, S; Jüngel, A (2010). Functional autoantibodies against serpin E2 in rheumatoid arthritis. Arthritis and Rheumatism, 62(1):93-104.

Marquart, S; Zerr, P; Akhmetshina, A; Palumbo, K; Reich, N; Tomcik, M; Horn, A; Dees, C; Engel, M; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2010). Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and Rheumatism, 62(11):3467-3476.

Distler, J H W; Distler, O (2010). Inflammation: Microparticles and their roles in inflammatory arthritides. Nature Reviews. Rheumatology, 6(7):385-386.

Maurer, B; Stanczyk, J; Jüngel, A; Akhmetshina, A; Trenkmann, M; Brock, M; Kowal-Bielecka, O; Gay, R E; Michel, B A; Distler, J H W; Gay, S; Distler, O (2010). MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism, 62(6):1733-1743.

Reich, N; Maurer, B; Akhmetshina, A; Venalis, P; Dees, C; Zerr, P; Palumbo, K; Zwerina, J; Nevskaya, T; Gay, S; Distler, O; Schett, G; Distler, J H W (2010). The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis and Rheumatism, 62(1):280-290.

Distler, J H W; Distler, O (2010). Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Annals of the Rheumatic Diseases, 69 Sup:i48-i51.

Venalis, P; Maurer, B; Akhmetshina, A; Busch, N; Dees, C; Stürzl, M; Zwerina, J; Jüngel, A; Gay, S; Schett, G; Distler, O; Distler, J H W (2009). Lack of inhibititory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. Journal of Cellular and Molecular Medicine, 13(10):4185-4191.

Guiducci, S; Distler, J H W; Milia, A F; Miniati, I; Rogai, V; Manetti, M; Falcini, F; Ibba-Manneschi, L; Gay, S; Distler, O; Matucci-Cerinic, M (2009). Stiff skin syndrome: evidence for an inflammation-independent fibrosis? Rheumatology, 48(7):849-852.

Hemmatazad, H; Maciejewska Rodrigues, H; Maurer, B; Brentano, F; Pileckyte, M; Distler, J H W; Gay, R E; Michel, B A; Gay, S; Huber, L C; Distler, O; Jüngel, A (2009). Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis and Rheumatism, 60(5):1519-1529.

Beyer, C; Schett, G; Gay, S; Distler, O; Distler, J H W (2009). Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Research & Therapy, 11(2):220.

Akhmetshina, A; Dees, C; Busch, N; Beer, J; Sarter, K; Zwerina, J; Zimmer, A; Distler, O; Schett, G; Distler, J H W (2009). The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis and Rheumatism, 60(4):1129-1136.

Dragun, D; Distler, J H W; Riemekasten, G; Distler, O (2009). Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis and Rheumatism, 60(4):907-911.

Distler, J H W; Allanore, Y; Avouac, J; Giacomelli, R; Guiducci, S; Moritz, F; Akhmetshina, A; Walker, U A; Gabrielli, A; Müller-Ladner, U; Tyndall, A; Matucci-Cerinic, M; Distler, O (2009). EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Annals of the Rheumatic Diseases, 68(2):163-168.

Distler, J H W; Akhmetshina, A; Schett, G; Distler, O (2009). Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology, 48(2):98-103.

Akhmetshina, A; Venalis, P; Dees, C; Busch, N; Zwerina, J; Schett, G; Distler, O; Distler, J H W (2009). Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and Rheumatism, 60(1):219-224.

Distler, J H W; Beyer, C; Schett, G; Lüscher, T F; Gay, S; Distler, O (2009). Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis and Rheumatism, 60(11):3168-3179.

Akhmetshina, A; Dees, C; Pileckyte, M; Maurer, B; Axmann, R; Jüngel, A; Zwerina, J; Gay, S; Schett, G; Distler, O; Distler, J H W (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB Journal, 22(7):2214-2222.

Distler, J H W; Schett, G; Gay, S; Distler, O (2008). The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis and Rheumatism, 58(8):2228-2235.

Guiducci, S; Distler, J H W; Jüngel, A; Huscher, D; Huber, L C; Michel, B A; Gay, R E; Pisetsky, D S; Gay, S; Matucci-Cerinic, M; Distler, O (2008). The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism, 58(9):2845-2853.

Huber, L C; Distler, J H W; Moritz, F; Hemmatazad, H; Hauser, T; Michel, B A; Gay, R E; Matucci-Cerinic, M; Gay, S; Distler, O; Jüngel, A (2007). Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis and Rheumatism, 56(8):275-264.

Huber, L C; Jüngel, A; Distler, J H W; Moritz, F; Gay, R E; Michel, B A; Pisetsky, D S; Gay, S; Distler, O (2007). The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis, 12(2):363-374.

Distler, J H W; Jüngel, A; Huber, L C; Schulze-Horsel, U; Zwerina, J; Gay, R E; Michel, B A; Hauser, T; Schett, G; Gay, S; Distler, O (2007). Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis and Rheumatism, 56(1):311-322.

Distler, J H W; Jüngel, A; Huber, L C; Seemayer, C A; Reich, C F; Gay, R E; Michel, B A; Fontana, A; Gay, S; Pisetsky, D S; Distler, O (2005). The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 102(8):2892-2897.

Distler, J H W; Wenger, R H; Gassmann, M; Kurowska, M; Hirth, A K; Gay, S; Distler, O (2004). Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 50(1):10-23.

This list was generated on Thu Jul 27 11:27:24 2017 CEST.